Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration & dosage. Found 206 abstracts

no pagination
Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001 Nov 15;92(10):2639-47.
Szarka CE, Yao KS, Pfeiffer GR, Balshem AM, Litwin S, Frucht H, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect Prev. 2001 Jan;25(4):352-61.
Tapiero H, Tew KD, Gate L, Machover D. Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. Biomed Pharmacother. 2001 Sep;55(7):381-90.
Treat J, Damjanov N, Huang C, Zrada S, Rahman A. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Huntingt). 2001 May;15(5 Suppl 7):44-8.
Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res. 2001 Jan;104:127-48.
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH. [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil. 2000 Jul;28(7-8):576-83.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol. 2000 Dec;23(6):589-92.
Langer CJ, McAleer CA, Bonjo CA, Litwin S, Millenson M, Kosierowski R, Blankstein K, Alexander R, Ozols RF. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC). Eur J Cancer. 2000 Jan;36(2):183-93.
Lewis NL, Meropol NJ. Oral fluoropyrimidines in cancer treatment. Cancer Invest. 2000 Jan;18(8):747-60.
Movsas B. Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer. Cancer control : journal of the Moffitt Cancer Center. 2000 Jan;7(1):25-34.
Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7.
Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol. 2000 Feb;27(1 Suppl 2):40-7.
Schilder RJ, Goldberg M, Millenson MM, Movsas B, Rogatko A, Rogers B, Langer CJ. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer. 2000 Jan;27(1):37-45.
Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):8-10.
Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer. 1999 Mar 15;85(6):1226-33.
Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer. 1999 Jan 15;85(2):290-4.
Langer CJ. The role of tegafur/uracil in pulmonary malignancy. Drugs. 1999 Jan;58 Suppl 3:71-5.
Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999 Dec;45(5):1143-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration & dosage

administration & dosage Human therapeutic use drug therapy Female pathology Antineoplastic Combined Chemotherapy Protocols Male Middle Age Non-US Gov't Support US Gov't Support-PHS Aged Lung Neoplasms Paclitaxel adverse effects Non-Small-Cell Lung Carcinoma Treatment Outcome Survival Analysis Adult Ovarian Neoplasms Prognosis Carboplatin Combined Modality Therapy Squamous Cell Carcinoma Cisplatin radiotherapy 80 and over Aged adverse Deoxycytidine Uracil Disease-Free Survival Randomized Controlled Trials Adenocarcinoma metabolism Clinical Trials effects mortality Fluorouracil analogs & derivatives Disease Progression Neoplasm Staging drug effects use Stomach Neoplasms methods prevention & control chemically induced Antineoplastic Antimetabolites complications Severity of Illness Index Drug Dose-Response Relationship therapeutic Survival Rate Animal therapy Prospective Studies genetics Neoplasms Breast Neoplasms Colorectal Neoplasms Tegafur Antineoplastic Agents Retinoids secretion Local Neoplasm Recurrence Cell Line Glutathione Granulocyte Colony-Stimulating Factor Immunohistochemistry Tetrahydrofolate Dehydrogenase Oxidative Stress Agranulocytosis Salvage Therapy Hematopoietic Stem Cell Transplantation Cryotherapy dosage Karnofsky Performance Status Pain Diet Prostatic Neoplasms Folic Acid Deficiency Follow-Up Studies Palliative Care Viral Load etiology biosynthesis cytology Th1 Cells Amino Acid Sequence physiopathology Quality-Adjusted Life Years Oral Administration Cell Division Practice Guidelines Nutritional Status Combination Drug Therapy Highly Active Antiretroviral Therapy Lymph Nodes Retrospective Studies US Gov't Support-Non-PHS NAD(P)H Dehydrogenase (Quinone) Drug Combinations Anthracyclines Liposomes Homocysteine immunology DNA Interferons Skin Diseases HLA-A2 Antigen diagnosis Immunologic Adjuvants Anticarcinogenic Agents Adjuvant Chemotherapy Cytokines Thoracotomy Physical Examination physiology Multiple Drug Resistance Philadelphia Phase III Clinical Trials Hematopoietic Stem Cell Mobilization Neoplasm Proteins Interferon-alpha Respiratory Tract Neoplasms Risk Factors CD4 Lymphocyte Count Phase I Clinical Trials Patient Selection Drug Synergism Conformal Radiotherapy Doxorubicin Biological Tumor Markers Tetanus Toxoid secondary Hormone-Dependent Neoplasms Etoposide Pyridines Antiviral Agents Saponins Pilot Projects Estramustine Time Factors Drug Administration Schedule Brachytherapy Skin Cervix Neoplasms Hiv-1 Neoplasm Metastasis Radiation Dosage
Last updated on Friday, January 03, 2020